<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928393</url>
  </required_header>
  <id_info>
    <org_study_id>BP29937</org_study_id>
    <secondary_id>2015-003227-66</secondary_id>
    <nct_id>NCT02928393</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety, Efficacy and Pharmacodynamic Study of Basmisanil (RO5186582) in Adults With Severe Motor Impairment Following an Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will
      evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with
      severe motor impairment following an ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low participant enrolment
  </why_stopped>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Actual">November 5, 2017</completion_date>
  <primary_completion_date type="Actual">November 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in FMMS Score at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Baseline (Day 1) up to 28 days after last dose of study drug (latest at Day 118)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Day 30</measure>
    <time_frame>Baseline (Day 1), Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in MoCA Score at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in National Institute of Health Stroke Scale (NIHSS) Score At Day 3</measure>
    <time_frame>Baseline (Day 1), Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in NIHSS Score At Day 10</measure>
    <time_frame>Baseline (Day 1), Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in NIHSS Score At Day 30</measure>
    <time_frame>Baseline (Day 1), Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in NIHSS Score At Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in NIHSS Score At 28 Days After Last Dose</measure>
    <time_frame>Baseline (Day 1) and at 28 days after last dose of study drug (latest on Day 118)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score At Day 3</measure>
    <time_frame>Baseline (Day 1), Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in C-SSRS Score At Day 30</measure>
    <time_frame>Baseline (Day 1), Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in C-SSRS Score At Day 60</measure>
    <time_frame>Baseline (Day 1), Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in C-SSRS Score At Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in C-SSRS Score At 28 Days After Last Dose</measure>
    <time_frame>Baseline (Day 1), at 28 days after last dose of study drug (latest on Day 118)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Rankin Scale (mRS) Score At Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS Score At Day 90</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fugl-Meyer Assessment (FMA) Total Score at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FMA Subscale Score at Day 90</measure>
    <time_frame>Baseline (Day 1), Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Basmisanil</measure>
    <time_frame>Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Basmisanil</measure>
    <time_frame>Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady States (Vss) of Basmisanil</measure>
    <time_frame>Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC] of Basmisanil</measure>
    <time_frame>Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Basmisanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to basmisanil orally twice daily for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basmisanil</intervention_name>
    <description>Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.</description>
    <arm_group_label>Basmisanil</arm_group_label>
    <other_name>RO5186582</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiologic assessment confirming an acute middle cerebral artery ischemic stroke

          -  Index stroke occurred within the past 3-4 days

          -  Inpatient males and females

          -  Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (&lt;/=) 35

          -  Sufficient speech, vision and hearing to participate in study evaluations

        Exclusion Criteria:

          -  NIHSS greater than (&gt;) 20

          -  Severe aphasia that prevents a participant from following directions in rehabilitation

          -  Significant deficit from prior strokes or pre-existing motor deficit

          -  History of epilepsy, neurosurgery, severe head trauma or central nervous system
             infections that have residual symptomatology or have required treatment in the last 12
             months

          -  Known or suspected clinical seizure post-index stroke

          -  History of pre-existing dementia or use of medications for dementia

          -  History of clinically significant pre-existing psychiatric conditions within 12 months
             prior to stroke

          -  Due to undergo carotid surgery within the next 4 months

          -  Enrollment/participation in any interventional study (clinical trial) involving an
             investigational drug (unapproved) or non-drug treatment within the prior 3 months or 6
             times the half-life (whichever is longer)

          -  Clinically relevant medical conditions that would likely interfere with the study
             conduct and scheduled assessments

          -  Contraindication to magnetic resonance imaging (MRI) or conditions which render
             interpretation of MRI difficult
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besancon Hopital Jean Minjoz; Service de Neurologie</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin Tripode - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital la Cavale Blanche</name>
      <address>
        <city>brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital General; Hôpital du Bocage - Service de neurologie</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clnico Universitario de Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Motor impairment</keyword>
  <keyword>Stroke recovery</keyword>
  <keyword>Middle cerebral artery stroke</keyword>
  <keyword>Fugl Meyer</keyword>
  <keyword>Fugl-Meyer Motor Scale (FMMS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

